Kyntra Bio
KYNB
32 hedge funds and large institutions have $7.01M invested in Kyntra Bio in 2026 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 8 closing their positions.
9,257% more call options, than puts
Call options by funds: $655K | Put options by funds: $7K
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
2.88% less ownership
Funds ownership: 28.45% → 25.57% (-2.9%)
6% less funds holding
Funds holding: 34 → 32 (-2)
31% less capital invested
Capital invested by funds: $10.1M → $7.01M (-$3.09M)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Birchview Capital
Burlington,
Vermont
|
+$177K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$142K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$18K |
| 4 |
HI
Harbour Investments
Madison,
Wisconsin
|
+$1.56K |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$1.51K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$285K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
-$267K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$147K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$113K |
| 5 |
Squarepoint
New York
|
-$107K |
KYNB Hedge Fund Activity: Q1 2026 in Review
32 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q1 2026, worth a combined $7.01M — down 31% from $10.1M a quarter earlier.
Fund positioning in KYNB was balanced in Q1 2026: 8 funds opened new positions, 8 closed out, 5 added to existing stakes and 8 trimmed.
The largest buyer was Birchview Capital, opening a new position worth an estimated $177K. The largest seller was Marshall Wace, exiting entirely with an estimated $285K sold.
- 32 institutional investors held Kyntra Bio (KYNB) as of Q1 2026, down from 34 in Q4 2025.
- Funds reported $7.01M of Kyntra Bio stock for Q1 2026, down 31% quarter-over-quarter.
- 8 funds opened new Kyntra Bio positions in Q1 2026 and 8 closed out, a net change of 0 holders.
- The largest Kyntra Bio buyer in Q1 2026 was Birchview Capital, an estimated $177K added.
- The largest Kyntra Bio seller in Q1 2026 was Marshall Wace, an estimated $285K sold.
Based on aggregated 13F filings for Q1 2026.